论文部分内容阅读
维司力农（vesnarinone，OPC－8212）是一种新型正性肌力药物。美国最近的多中心随机试验证实，每天使用本品60mg可显著减少慢性心衰（症状性）的并发症和死亡率，从而改善这类患者的生存质量。为进一步评价维司力农的疗效和安全性，美国又进行了大量长期用药研究。现已报告的?
Vesnarinone (OPC-8212) is a new type of inotropic agent. A recent multicenter randomized trial in the United States confirms that the daily use of 60 mg of this product significantly reduces the complication and mortality of chronic heart failure (symptomatic) and thus improves the quality of life of these patients. In order to further evaluate the efficacy and safety of Vernilon, the United States conducted a large number of long-term medication studies. Now reported?